Concepedia

Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy

Yeon-Suk Yang, Jun Xie, Sachin Chaugule, Dan Wang, Jung‐Min Kim, JiHea Kim, Phillip W.L. Tai, Seok Kyo Seo, Ellen M. Gravallese, Guangping Gao,

Molecular Therapy — Methods & Clinical Development · 2020 · 49 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

is a promising gene therapy that can preserve bone formation and mitigate osteoporosis, while limiting adverse off-target effects.

References

35

Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density

W. Scott Simonet, Dave Lacey, Colin R. Dunstan et al. · Cell · 1997 · 5.1K citations · Full text

, , +13

Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee

A. M. Parfitt, Marc K. Drezner, Francis H. Glorieux et al. · Journal of Bone and Mineral Research · 1987 · 5K citations

, , +12

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

Young‐Yun Kong, Hiroki Yoshida, Ildiko Sarosi et al. · Nature · 1999 · 3.4K citations

, , +14

RANK is essential for osteoclast and lymph node development

William C. Dougall, Moira Glaccum, K Charrier et al. · Genes & Development · 1999 · 1.5K citations · Full text

, , +13

Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes

Kevin D. Foust, Emily Nurre, Chrystal L. Montgomery et al. · Nature Biotechnology · 2008 · 1.4K citations · Full text

, , +8